Progress in Mind
チャンネルを選ぶ
いろいろなProgress in Mindのコンテンツを見てみる。
Detail Tag
| ID | Term Name |
|---|---|
| 85 | QoL |
| 86 | Cognition |
| 87 | Co-morbidities |
| 88 | Adherence |
| 89 | Treatment resistance |
| 90 | Diagnosis |
| 91 | Stigma |
| 92 | Pharmacology |
| 93 | Biomarkers |
| 94 | Technology |
| 95 | Comorbidity |
| 96 | Treatment |
| 97 | Research |
| 98 | Nonclinical |
| 99 | Preclinical |
| 100 | Symptoms |
| 101 | Aetiology |
| 102 | Relapse |
| 103 | Response |
| 104 | Carer |
| 105 | Patient management |
| 106 | Physical health |
| 108 | DSM5 |
| 109 | DSM-5 |
| 112 | Pathogenesis |
| 113 | Pathology |
| 116 | Remission |
| 117 | Compliance |
| 118 | Suicide |
| 119 | Prevention |
| 120 | Prognosis |
| 121 | Genetics |
| 150 | MDD |
| 151 | Neurocognition |
| 152 | Psychology |
| 153 | Psychosis |
| 154 | Weight-gain |
| 155 | First-episode |
| 156 | Antipsychotics |
| 157 | Lifestyle |
| 158 | Quality of Life |
| 159 | First episode |
| 160 | Comic |
| 161 | Disease management |
| 162 | Epidemiology |
| 163 | Screening |
| 164 | Burden |
| 165 | Course of disease |
| 166 | Functional outcome |
| 167 | Residual symptoms |
| 168 | Switching treatment |
| 169 | Placebo effect |
| 170 | Metabolic risks |
| 171 | Mania64 |
| 172 | Questionnaires |
| 173 | Causes |
| 174 | Mania with depressive symptoms |
| 175 | Bipolar I management |
| 176 | Cognitive impairment |
| 177 | Agitation |
| 179 | Irritability |
| 180 | Top of the Polls |
| 181 | Blog post |
| 182 | Bipolar I treatment |
| 183 | Mania |
| 184 | Opinion piece |
| 191 | SNC |
| 192 | Various |
| 197 | Endophenotype |
| 198 | Review |
| 201 | Management |
| 202 | Management. Diagnosis |
| 203 | Course of the disease |
| 204 | Physical function |
| 205 | Social function |
| 206 | Latest thinking |
| 207 | Events |
| 208 | Cognitive dysfunction |
| 209 | THINC-it tool |
| 210 | Impaired function |
| 211 | Inadequate response |
| 212 | Working |
| 213 | Daily life |
| 215 | Depression |
| 216 | Cognitive deficit |
| 217 | Function |
| 218 | Work |
| 219 | Under-managed |
| 220 | Depression; Comorbidity; Substance use disorders; Dopamine |
| 221 | First episode psychosis |
| 222 | Post-Traumatic Stress Disorder (PTSD); Dementia; Alzheimer’s disease; PET imaging |
| 223 | Depression; Stress; Resilience; HPA axis |
| 224 | Depression; Inflammation; Immune markers; Cytokines; Biomarkers; Suicide |
| 225 | Depression; Bipolar disorder |
| 226 | Dual disorders; Depression; Schizophrenia; Bipolar disorder; Substance use |
| 227 | Schizophrenia; Caregiver; Employment; Productivity |
| 231 | Depression; Cognitive deficit; Function; Work; Under-managed |
| 232 | Culture |
| 233 | Society |
| 234 | Socio-cultural |
| 235 | Research; Pharmacology; |
| 236 | psychiatry; young scientists; researchers; medical education |
| 237 | psychiatry; researchers; medical education |
| 238 | neuropsychopharmacology; medical education; CINP; psychiatry |
| 239 | schizophrenia; imaging; dopaminergic circuitry; psychiatry |
| 240 | schizophrenia; dopamine; imaging; deficits; dysfunction |
| 241 | computational neuroscience; imaging biomarkers; autism; schizophrenia; depression |
| 242 | MedEd |
| 244 | Alzheimer; Demência; |
| 245 | Variedades |
| 246 | Diagnóstico |
| 247 | suicídio |
| 248 | prevenção |
| 249 | Quadrinhos |
| 250 | Vários |
| 253 | Risk |
| 254 | Assessment |
| 255 | Reseach |
| 259 | Psychopharmacology |
| 260 | Neuroimaging |
| 262 | Depresión; Estres; Resilencia; HPA axis |
| 263 | Cognición |
| 264 | Tecnología |
| 265 | Investigación |
| 266 | Salud física |
| 267 | Riesgo metabólico |
| 268 | Sintomas residuales |
| 269 | TDM |
| 270 | Neurocognición |
| 271 | Psicología |
| 272 | Síntomas |
| 273 | Depresión; Inflamación; Marcadores inmunológicos; Biomarcadores; Suicidio; Citocinas |
| 274 | Depresión |
| 275 | Transtorno Bipolar |
| 276 | Schizophrenia |
| 277 | Full Functional Recovery |
| 278 | Functioning |
| 280 | etiología |
| 281 | Epidemiología |
| 282 | Genética |
| 283 | manejo |
| 284 | patología |
| 285 | tratamiento |
| 286 | trastorno bipolar |
| 287 | formación médica |
| 288 | formación |
| 289 | actualización |
| 290 | enfermedad mental |
| 291 | psiquiatría |
| 292 | neurología |
| 293 | Vieta |
| 294 | Bipolar Disorder |
| 295 | psychiatry |
| 296 | Risks |
| 300 | aetioogy |
| 301 | Comorbidities |
| 302 | Sleep |
| 304 | Summary of Recent Paper |
| 305 | Europeandepressionday |
| 306 | Thethincittool |
| 307 | Thincittool |
| 308 | Eziologia |
| 309 | Prevenzione |
| 310 | Rischio |
| 311 | Depressione |
| 312 | Schizofrenia |
| 313 | Salute Mentale |
| 314 | Preclinica |
| 315 | Sonno |
| 316 | Trattamento |
| 317 | Fattori di Rischio |
| 318 | SOPSI |
| 320 | Caregivers |
| 322 | Scientific Association |
| 323 | Age of onset |
| 324 | Sexual abuse |
| 325 | Genetic loading |
| 326 | ICD-10 |
| 327 | Debate |
| 328 | The concept of schizophrenia |
| 329 | Split mind |
| 330 | Curso de la enfermedad |
| 331 | Primer episodio |
| 332 | Edad de inicio |
| 333 | Abuso sexual |
| 334 | Carga genética |
| 335 | Access to treatments |
| 336 | social cognition |
| 337 | Disorganized schizophrenia |
| 338 | Mentalizing deficits |
| 339 | Negative symptoms |
| 340 | Voice from the floor |
| 341 | Inflammation |
| 342 | Pro-inflammitory cytokines |
| 343 | Default mode network |
| 344 | Mixed states |
| 345 | ICD-11 |
| 346 | MDS – 200 Years of PD |
| 347 | Computational neuroscience |
| 348 | Imaging biomarkers |
| 349 | Autism |
| 350 | Dopamine |
| 351 | Imaging |
| 352 | Deficits |
| 353 | Dysfunction |
| 354 | Dopaminergic circuitry |
| 355 | Researchers |
| 356 | Medical education |
| 357 | Young scientists |
| 358 | European Commission |
| 359 | MRI-based predictive models |
| 360 | PRONIA |
| 361 | TRIMAGE |
| 362 | IMAGEMEND |
| 363 | OPTiMiSE |
| 364 | Personalized medicine |
| 365 | Autism spectrum disorders |
| 366 | Neuronale correlates |
| 367 | Brain organoids |
| 368 | Altered connectivity |
| 369 | Dual disorders |
| 370 | Substance use |
| 371 | Stress |
| 372 | Resilience |
| 373 | HPA axis |
| 374 | Caregiver |
| 375 | Employment |
| 376 | Productivity |
| 377 | Immune markers |
| 378 | Cytokines |
| 379 | Post-Traumatic Stress Disorder (PTSD) |
| 380 | Dementia |
| 381 | Alzheimer’s disease |
| 382 | PET imaging |
| 383 | Substance use disorders |
| 385 | Negative symptoms of schizophrenia |
| 386 | Neuroimagining |
| 387 | Motivation-related symptoms |
| 388 | deficit in expression |
| 389 | Diagnonsis |
| 390 | Schizophrenia subtypes |
| 391 | Deficit schizophrenia |
| 392 | Treatment resistant schizophrenia |
| 393 | Novel Markers |
| 394 | Tool to predict outcome |
| 395 | Gender identity |
| 396 | Gender dysporia |
| 397 | Gender reassignment |
| 398 | CdV |
| 399 | Prevención |
| 400 | Aderencia |
| 402 | Length of stay |
| 403 | 10 days |
| 404 | Readmission |
| 405 | Starting treatment |
| 406 | Long-term |
| 407 | Movie Comment |
| 412 | guideline |
| 413 | APA |
| 414 | Registry |
| 415 | One year after |
| 416 | Madrid 2017 |
| 437 | Endofenotipo |
| 438 | CIE-10 |
| 439 | Red neuronal por defecto |
| 440 | Cognición social |
| 441 | Estados mixtos |
| 442 | CIE-11 |
| 444 | Interview |
| 445 | Diagnotic challenges |
| 446 | Mixed episodes |
| 447 | Medical comorbidity |
| 448 | Cognitive symptoms |
| 449 | Predictors of response |
| 450 | Prof Andrea Fagiolini |
| 451 | Neurology |
| 452 | Unmet Needs |
| 454 | workplace |
| 455 | world mental health day |
| 456 | mental health |
| 457 | brain |
| 460 | Schizophrenia; Remission; Treatment |
| 461 | Clinical |
| 462 | Memory and cognitive disorders |
| 463 | Functional impairment |
| 464 | Biological markers |
| 465 | Diagnoses and classification |
| 466 | Methodology |
| 467 | Functional improvement |
| 468 | Long acting injectable antipsychotics (LAIs) |
| 469 | Clinical outcomes |
| 470 | Determinants of outcome |
| 471 | Patient preference for outcomes |
| 472 | Stated preference methodology |
| 473 | Patient-tailored management of schizophrenia |
| 474 | Doctor’s perspective |
| 475 | Neurotoxicity |
| 476 | Continuous treatment |
| 477 | Diagnoses & classification |
| 478 | RDoC |
| 479 | Transdiagnostic research |
| 481 | Congreso Nacional de Psiquiatría Legal |
| 482 | Satellite Symposium |
| 483 | Remission |
| 484 | E-Health Tool |
| 485 | Treatment Selection in Schizpophrenia |
| 486 | Treatment resistant schizophrenia (TRS) |
| 487 | Treatment algorithms for TRS |
| 488 | Treatment option for TRS |
| 489 | Insomnia |
| 490 | Animal models |
| 491 | Growth factors |
| 492 | Biomakers |
| 493 | psychoneuroendocrinology |
| 494 | neurosteroids |
| 495 | depression stress |
| 496 | Symptoms |
| 497 | Scientific Exchange |
| 498 | Top paper session |
| 499 | Highlights |
| 500 | GPC |
| 501 | glial progenitor cell |
| 502 | HDAC |
| 503 | histone deacetylase |
| 505 | Schizophrenia and Functioning |
| 506 | D2 Partial Antagonist Antipsychotics |
| 507 | Pharmacology of D2 Partial Agonists |
| 508 | Role of Partial D2 Agonist in Schizophrenia |
| 509 | D2 Partial Agonist and Functioning |
| 510 | clinical Study Results and Functioning |
| 511 | Course of disease; patient management; prevention; ECNP patient session |
| 512 | Congnición |
| 513 | puesto de trabajo |
| 514 | día mundial de la salud mental |
| 515 | salud mental |
| 516 | cerebro |
| 517 | Trastorno por consumo de alcohol |
| 518 | Abordaje integral |
| 519 | entrevista motivacional |
| 521 | molecular genetics |
| 522 | calcium |
| 523 | aethiology |
| 525 | Esquizofrenia |
| 526 | Simposio |
| 527 | Congreso nacional de psiquiatría 2017 |
| 528 | Alzheimer |
| 529 | depression: clinical |
| 530 | Early treatment |
| 531 | Measurement-based care |
| 532 | Confidence in treatment |
| 533 | GABA |
| 534 | Schizophrenia basic |
| 538 | aidant/travailleur social |
| 539 | patient care |
| 540 | during illness |
| 541 | premier épisode |
| 542 | recherche |
| 543 | QdV |
| 544 | Prise en charge de la maladie ; Prise en charge du patient |
| 545 | Symptoms |
| 546 | Evaluation |
| 547 | Évolution de la maladie |
| 548 | Gestion thérapeutique |
| 549 | Prise en charge des patients |
| 550 | Risques |
| 551 | Processing |
| 552 | Qualité de vie |
| 553 | Étiologie |
| 554 | Réponse inadéquate |
| 555 | Biomarcadores Patología |
| 557 | FAST |
| 558 | Escala de evaluación funcional |
| 559 | HAM-D |
| 560 | Escala de depresión de Hamilton |
| 561 | Calidad de vida |
| 562 | epidémiologie |
| 563 | revue |
| 564 | génétiques |
| 565 | Aethiologie |
| 566 | pathologie |
| 567 | préclinique |
| 568 | entrevista |
| 569 | expertos |
| 570 | psiquiatras |
| 571 | trastornobipolar |
| 572 | paciente |
| 573 | metabolico |
| 574 | depresion. mensaje |
| 575 | 1802PIM03 |
| 576 | diagnostic |
| 577 | fardeau |
| 578 | rechute |
| 580 | disease management |
| 582 | santé physique |
| 583 | schizophrénie |
| 584 | imagerie |
| 585 | trouble déficitaire |
| 586 | dysfonctionnement |
| 587 | 질병의 관리 |
| 588 | 환자 관리 |
| 589 | 예방 |
| 590 | 약리학 |
| 591 | 항정신병약 |
| 592 | 병리학 |
| 593 | 역학 |
| 594 | 전임상 |
| 595 | 동반질환 |
| 596 | 신체 건강 |
| 597 | 관해(remission) |
| 598 | 인지기능 |
| 599 | 삶의 질(QoL) |
| 600 | 증상 |
| 601 | 병인 |
| 602 | 유전학 |
| 603 | 리뷰 |
| 604 | 치료 |
| 605 | 사회적 부담 |
| 606 | 질병의 경과 |
| 607 | dormir |
| 608 | 평가 |
| 609 | 연구 |
| 610 | 바이오마커 |
| 611 | 순응도 |
| 612 | 진단 |
| 613 | 자살 |
| 615 | Neural networking |
| 616 | Insight |
| 617 | THINC-it |
| 618 | Real-world evidence |
| 619 | CBT |
| 620 | Executive function |
| 621 | Recovery |
| 622 | Real-worlds evidence |
| 623 | MADRS |
| 624 | mechanism of action |
| 626 | Classification |
| 627 | Meta-analyses |
| 628 | Individualized therapy |
| 629 | treatent |
| 630 | Polypharmacy |
| 631 | Antypsychotics |
| 632 | Adverse events |
| 633 | Cognitive remediation |
| 634 | Metacognition |
| 635 | Ultra-high risk |
| 636 | Early Intervention |
| 637 | ARMS |
| 638 | Early detection |
| 640 | Illness |
| 641 | Phenotype |
| 642 | Experience |
| 643 | Interpretation |
| 644 | Functional recovery |
| 645 | Policy |
| 646 | Stakeholder involvement |
| 647 | Sintomas cognitivos |
| 648 | EPA |
| 649 | Telepsychiatry |
| 650 | Education |
| 651 | Peer support |
| 652 | Resource |
| 653 | Pathophysiology |
| 654 | Pharmacogenetics |
| 655 | Stratification |
| 656 | Neuroanatomy |
| 658 | Patient managmeent |
| 659 | Nutrition |
| 660 | Multidomain intervention |
| 661 | Diet |
| 662 | Amyloid |
| 663 | Hypometabolism |
| 664 | Astrocytosis |
| 665 | Neuroradiology |
| 666 | Target |
| 667 | Tau |
| 668 | Microglial inflammation |
| 669 | Time course |
| 670 | Microbiota |
| 671 | LPS |
| 672 | Escherichia coli |
| 673 | Microbiome |
| 674 | Gram-negative bacteria |
| 675 | Bacteroides fragilis |
| 676 | Publich Health |
| 677 | Cardiovascular Disease |
| 678 | obesity |
| 679 | Centiloid |
| 680 | Trial |
| 681 | Diagnosis Genetics |
| 682 | Prelinical |
| 683 | GBA |
| 684 | GCase |
| 685 | UPSIT |
| 686 | DAT imaging |
| 687 | Patient |
| 688 | Early interventions |
| 689 | Funcitoning |
| 690 | Network |
| 691 | New definition |
| 692 | Mental illness |
| 693 | cogniiton |
| 694 | public health |
| 695 | at-risk children |
| 696 | family history |
| 697 | Disclosure |
| 698 | Symptom overlap |
| 699 | MRI |
| 700 | Computing |
| 701 | Wearable technology |
| 702 | Big Data |
| 703 | Machine learning |
| 704 | Cluster |
| 705 | Genotype |
| 706 | Stress response |
| 707 | PTSD |
| 708 | Person-centered approach |
| 709 | VAST-D |
| 710 | Treatment-resistant Schizophrenia |
| 711 | TRS |
| 712 | Care recipient |
| 713 | Consequences |
| 714 | Health |
| 715 | stigmate |
| 716 | Διαχείριση ασθενούς |
| 717 | Υποτροπή |
| 718 | Διαχείριση της νόσου |
| 719 | Πρώτο επεισόδιο |
| 720 | Θεραπεία |
| 721 | Φορτίο |
| 722 | Πορεία της νόσου |
| 723 | 예후 |
| 724 | Αξιολόγηση |
| 725 | Γνωσιακή λειτουργία |
| 726 | Ύφεση |
| 727 | Διάγνωση |
| 728 | Έλεγχος |
| 729 | Συμπτώματα |
| 730 | esquizofrenia resistente al tratamiento |
| 731 | CATIE |
| 732 | intervencion temprana |
| 733 | esquizofrenia resistente |
| 734 | Αντιψυχωτικά |
| 735 | psychose |
| 736 | pharmacologie |
| 737 | personnels soignants et aidants |
| 738 | biomarqueurs |
| 739 | 스크리닝 |
| 740 | THINC® |
| 742 | Λειτουργικότητα στη Σχιζοφρένεια |
| 743 | video |
| 745 | Cardiovascular Disease |
| 746 | obesity |
| 747 | Network |
| 748 | New definition |
| 749 | Mental illness |
| 750 | Telepsychiatry |
| 751 | Education |
| 752 | Peer support |
| 753 | Resource |
| 754 | treatent |
| 755 | Polypharmacy |
| 756 | Antypsychotics |
| 757 | Adverse events |
| 758 | THINC-it |
| 759 | Real-world evidence |
| 760 | CBT |
| 761 | Executive function |
| 762 | Pathophysiology |
| 763 | Pharmacogenetics |
| 764 | Stratification |
| 765 | Neuroanatomy |
| 766 | Neural networking |
| 767 | Insight |
| 768 | Meta-analyses |
| 769 | Individualized therapy |
| 770 | Cognitive remediation |
| 771 | Metacognition |
| 772 | Ultra-high risk |
| 774 | Centiloid |
| 775 | Amyloid |
| 776 | Trial |
| 777 | Patient managmeent |
| 778 | Nutrition |
| 779 | Multidomain intervention |
| 780 | Diet |
| 781 | Microbiota |
| 782 | LPS |
| 783 | Escherichia coli |
| 784 | Microbiome |
| 785 | Gram-negative bacteria |
| 786 | Bacteroides fragilis |
| 787 | Hypometabolism |
| 788 | Astrocytosis |
| 789 | Neuroradiology |
| 790 | Target |
| 791 | Tau |
| 792 | Microglial inflammation |
| 793 | Time course |
| 794 | Diagnosis Genetics |
| 795 | Prelinical |
| 796 | GBA |
| 797 | GCase |
| 798 | UPSIT |
| 799 | DAT imaging |
| 800 | Publich Health |
| 801 | Early Intervention |
| 802 | ARMS |
| 803 | Early detection |
| 804 | Patient |
| 805 | Early interventions |
| 806 | Funcitoning |
| 808 | Policy |
| 809 | Stakeholder involvement |
| 810 | Illness |
| 811 | Phenotype |
| 812 | Experience |
| 813 | Interpretation |
| 814 | Functional recovery |
| 815 | cogniiton |
| 816 | public health |
| 817 | at-risk children |
| 818 | family history |
| 819 | Disclosure |
| 820 | Assess ment |
| 821 | Cognitive behavioral therapy |
| 822 | Rating scales |
| 823 | Microcircuits |
| 824 | Macrocircuits |
| 826 | Classification |
| 827 | Recovery |
| 828 | Real-worlds evidence |
| 829 | MADRS |
| 830 | HAM-D |
| 831 | mechanism of action |
| 832 | Genotype |
| 833 | Stress response |
| 834 | PTSD |
| 835 | Person-centered approach |
| 836 | VAST-D |
| 837 | Symptom overlap |
| 838 | MRI |
| 839 | Computing |
| 840 | Wearable technology |
| 841 | Big Data |
| 842 | Machine learning |
| 843 | Cluster |
| 844 | Social media |
| 845 | campaign |
| 846 | Anti-stigma |
| 847 | Immunotherapy |
| 848 | Dose |
| 849 | Disease-modifying therapy |
| 850 | PK/PD modeling |
| 851 | Collaborative care |
| 852 | Care manager |
| 853 | ISER |
| 854 | QALY |
| 855 | Treatment-resistant Schizophrenia |
| 856 | TRS |
| 857 | Care recipient |
| 858 | Consequences |
| 859 | Health |
| 860 | Therapeutic strategy |
| 861 | Positive symptoms |
| 863 | Environment |
| 864 | Urban |
| 865 | Nature |
| 866 | Brain activity |
| 867 | Public--Private partnership |
| 868 | Phenotyping |
| 869 | Biotype |
| 870 | Brain connectivity |
| 871 | LAI |
| 872 | Antipsychotic |
| 873 | Hospitalization |
| 874 | Efficacy |
| 875 | Tolerability |
| 876 | Weight |
| 877 | Side effect |
| 878 | Παραμονή στη θεραπεία |
| 879 | Comobidity |
| 880 | Substance abuse |
| 881 | OCD |
| 882 | OnTrackNY |
| 883 | PEPPNET |
| 884 | RAISE |
| 885 | FEP |
| 886 | NAVIGATE |
| 887 | COMPASS |
| 888 | STEP-ED |
| 889 | MOST |
| 890 | Metanalysis |
| 891 | Trajectory analysis |
| 892 | Prodrome |
| 893 | Attenuated Psychosis Syndrome |
| 894 | Synaptic pruning |
| 895 | Hippocampus |
| 896 | CA1 |
| 897 | Field studies |
| 898 | WHO |
| 899 | PET |
| 900 | DBS |
| 901 | Gait |
| 902 | Deep brain stimulation |
| 903 | Coulse of Disease |
| 904 | Formulation |
| 905 | Alpha-synuclein |
| 906 | Levodopa |
| 907 | -course of disease |
| 908 | Trajectory |
| 909 | Development |
| 910 | Neurogenesis |
| 911 | 22q11.2 |
| 912 | Therapeutic target |
| 913 | COMT |
| 914 | Tbx1 |
| 915 | Variant |
| 916 | Algorithm |
| 917 | Longitudinal database |
| 918 | Observational database |
| 919 | Identification |
| 920 | Epigenetics |
| 921 | Outcome |
| 922 | Variables |
| 923 | Treatment response |
| 924 | Predictor |
| 925 | Editorial Board Meeting |
| 926 | Observance |
| 927 | pronostic |
| 928 | résultats sur le fonctionnement |
| 930 | Probiotics |
| 931 | EBM |
| 932 | Neuronal circuitry |
| 933 | Burden of disease |
| 935 | Drug targets |
| 936 | Risk factor |
| 937 | Weight gain |
| 938 | Metabolic disease |
| 939 | Tratment |
| 940 | Real-world |
| 941 | Clinical practice |
| 942 | Safety |
| 943 | Partial agonist |
| 944 | D2 receptor |
| 945 | Brain Shrinkage |
| 946 | Outcomes |
| 947 | Patholoy |
| 948 | 22q11.2 microdeletion |
| 949 | mechanism |
| 950 | translation |
| 951 | Therapeutic targets |
| 952 | Behavior |
| 953 | 아포지단백E |
| 954 | Late life depression |
| 955 | Neuroinflammation |
| 956 | Motivation |
| 957 | Cognitive Remediation Therapy |
| 958 | Social functioning |
| 959 | Prescribing |
| 961 | Normative modeling |
| 962 | Connectivity |
| 963 | Antidepressant |
| 964 | Prediction |
| 965 | Brain circuit |
| 967 | 우울증 |
| 968 | 인지증상 |
| 969 | 당뇨병 |
| 970 | Network dysfunction |
| 971 | EEG |
| 972 | Magneto-encephalography |
| 973 | Research networks |
| 974 | Drug development |
| 975 | MFS |
| 976 | 양극성장애 |
| 977 | 아동기 |
| 978 | 해마 |
| 979 | vie quotidienne |
| 980 | réponse |
| 981 | Psychosocial |
| 982 | Aging |
| 983 | Statistics |
| 984 | Wearable devises |
| 987 | John FP Bridges |
| 988 | 대한불안의학회 춘계학술대회 |
| 989 | 주요우울장애(MDD) |
| 990 | 대한불안의학회 |
| 992 | 대한신경정신의학회 춘계학술대회 |
| 993 | 콜레스테롤 |
| 994 | 스타틴 |
| 995 | AAIC 2018 |
| 997 | 간병인 |
| 998 | Manejo de la enfermedad |
| 999 | Manejo del paciente |
| 1000 | Respuesta Parcial |
| 1001 | Farmacología |
| 1002 | Dopamina |
| 1003 | Modelado normativo |
| 1004 | Conectividad |
| 1005 | Red |
| 1006 | Antidepresivo |
| 1007 | Predicción |
| 1008 | Respuesta |
| 1009 | Circuito cerebral |
| 1010 | guias terapeuticas |
| 1011 | CINP 2017 |
| 1012 | analisis |
| 1013 | evidencia clínica |
| 1014 | Disease mangement |
| 1015 | Cognitive assessment |
| 1016 | Multimodal interventions |
| 1017 | Medical education and training |
| 1018 | Student mental health |
| 1019 | Adherance |
| 1020 | Diabetes |
| 1021 | Dopamine D2 receptor agonists |
| 1022 | fonctionnement |
| 1023 | 주요우울장애 |
| 1024 | 영상 유전학 |
| 1025 | Shared decision-making |
| 1026 | Goal setting |
| 1027 | tools |
| 1028 | DSST |
| 1029 | PDQ |
| 1030 | Patient perspective |
| 1031 | Treatment goals |
| 1032 | Treatment choices |
| 1033 | Gut-brain axis |
| 1034 | 5HT2 |
| 1035 | Supersensitivity |
| 1036 | Antagonist |
| 1037 | Real-world data |
| 1038 | Effectiveness |
| 1039 | Workplace performance |
| 1040 | functional recovery |
| 1041 | Patient's goals |
| 1042 | stakeholder |
| 1043 | Lived experience |
| 1044 | Precision medicine |
| 1045 | Targeted therapy |
| 1046 | Therapeutic drug monitoring |
| 1047 | Life goals |
| 1048 | Costs |
| 1049 | Duration of untreated psychosis |
| 1050 | RAISE-ETP |
| 1051 | Subtyping |
| 1052 | Digital technology |
| 1053 | Monitoring |
| 1054 | OFF |
| 1055 | Freezing |
| 1056 | Exeercise |
| 1057 | 영상유전학 |
| 1061 | OPUS panel |
| 1062 | DUP |
| 1063 | Treatment delay |
| 1064 | Online intervention |
| 1065 | Teatment |
| 1066 | Patient goals |
| 1067 | Patient expectations |
| 1068 | Brain imaging |
| 1069 | Research Domain Criteria |
| 1070 | Amyloid-beta |
| 1071 | Apolipoprotein E |
| 1072 | Blood:brain barrier |
| 1073 | comorbidité |
| 1074 | neuroimagerie |
| 1075 | Glutamate |
| 1076 | NMDA receptor antagonists |
| 1077 | Neuroprogression |
| 1078 | Neuroprotection |
| 1079 | Severity |
| 1080 | Psychotherapy |
| 1081 | Diseasemanagement |
| 1082 | Stigma resistance |
| 1083 | Internalized stigma |
| 1084 | Long-acting injectable antipsychotic |
| 1085 | Clinical trials |
| 1086 | Early Alzheimer's disease |
| 1087 | Artificial intelligence |
| 1088 | Neurodevelopment |
| 1089 | Connectome |
| 1090 | Creativity |
| 1091 | Polyunsaturated fatty acids |
| 1093 | Transition to psychosis |
| 1094 | Cost |
| 1095 | Survey |
| 1096 | Awareness |
| 1097 | Neurobiology |
| 1098 | Burde |
| 1099 | Subtypes |
| 1100 | Disease heterogeneity |
| 1101 | Assessment. Cognition. Disease management. Patient management. Remission. Symptoms. Treatment. Function. |
| 1102 | ECNP |
| 1103 | funcionanildad |
| 1104 | sistema dopaminergico |
| 1105 | tolerabilidad |
| 1106 | Sexual functioning |
| 1107 | Mixed features |
| 1108 | DSM-5 MADRS |
| 1109 | PHQ-9 |
| 1110 | YMRS |
| 1111 | Science |
| 1112 | synapse |
| 1113 | Circuit |
| 1114 | Striatum |
| 1115 | Reverse emotional valence |
| 1116 | Disease managemet |
| 1117 | Long-acting injectable antipsychotic (LAI) |
| 1118 | Oral antipsychotic (OAP) |
| 1119 | Real world |
| 1120 | Mirror study |
| 1121 | Genetic |
| 1122 | NICE |
| 1123 | Clinical trial |
| 1124 | Early dialogues |
| 1125 | Evidence generation plans |
| 1126 | HTA |
| 1127 | Health ecnomics |
| 1128 | Patient-centered research |
| 1129 | Advocacy |
| 1130 | Patient engagement |
| 1131 | Healthcare |
| 1132 | 삶의 질 |
| 1134 | consenso |
| 1135 | recuperacion funcional |
| 1136 | documento |
| 1137 | abordaje compartido de la depresion |
| 1138 | Anxiété |
| 1139 | réseau par défaut |
| 1140 | Adeherance |
| 1141 | Functional MRI |
| 1142 | Networks |
| 1143 | Striatal functional recovery |
| 1144 | Striatal Connectivity index |
| 1145 | Hospital stay |
| 1146 | Mindfulness |
| 1147 | NYC START |
| 1148 | Fidelity scale |
| 1149 | Funding |
| 1150 | Service delivery |
| 1151 | Critical period |
| 1152 | Basket cell |
| 1153 | Parvalbumin |
| 1154 | Perineural net |
| 1155 | CHR |
| 1156 | SHARP study |
| 1157 | LIA |
| 1158 | DaT scan |
| 1159 | Differential diagnosis |
| 1160 | Early diagnosis |
| 1161 | Sequencing |
| 1162 | WGS |
| 1163 | WES |
| 1164 | ethics |
| 1165 | Whole genome sequencing |
| 1166 | Whole exome sequencing |
| 1167 | IRB |
| 1168 | Enhancer elements |
| 1170 | Prodromal |
| 1171 | Motor symptoms |
| 1172 | Non-motor symptoms |
| 1173 | Drug repurposing |
| 1174 | Biometric monitoring |
| 1175 | Electronic health records |
| 1176 | neuropathology |
| 1177 | Protein |
| 1178 | Misdiagnosis |
| 1179 | Fluid biomarker |
| 1180 | Solid biomarker |
| 1181 | 치매 |
| 1182 | 알츠하이머 |
| 1183 | Έρευνα |
| 1184 | psicosis |
| 1185 | perspectiva del paciente |
| 1186 | tratamiento de la esquizofrenia |
| 1188 | Disease managemnet |
| 1189 | Patient mangement |
| 1190 | evaluacion sintomatica |
| 1191 | efectos adversos |
| 1192 | enfoque de la depresión |
| 1193 | avances en depresión |
| 1194 | GDPR |
| 1195 | Digital health |
| 1196 | Healthcare delivery |
| 1197 | Real-world data |
| 1198 | Training |
| 1199 | Patient-relevant outcomes |
| 1200 | PROs |
| 1201 | Industry |
| 1202 | Label |
| 1203 | RCTs |
| 1204 | Cost-effectiveness |
| 1205 | Subgroup |
| 1206 | Funcitonal symptoms |
| 1207 | Clinical care |
| 1208 | Patient-focused drug development |
| 1209 | Patient-centered clinical care |
| 1210 | Podcast |
| 1211 | funcionalidad |
| 1212 | CIE 11 |
| 1213 | antipsicóticos |
| 1214 | 재발(relapse) |
| 1215 | neurotixina |
| 1216 | neurotixicidad |
| 1218 | atencion primaria |
| 1219 | resistance au traitement |
| 1220 | thinc it tool |
| 1223 | Bipolar |
| 1224 | 기술 |
| 1226 | Philip Gorwood |
| 1227 | trastorno depresivo mayor |
| 1228 | Πρόληψη |
| 1229 | Επίδραση του εικονικού σκευάσματος |
| 1230 | Trial designs |
| 1231 | Amyloid beta |
| 1232 | Neurofilament light chain |
| 1233 | Lewy body disease LBD |
| 1234 | Multiple system atrophy MSA |
| 1235 | PPMI |
| 1236 | Alpha synuclein |
| 1237 | Neurogranin |
| 1238 | Enteric nervous system |
| 1239 | Lewy bodies |
| 1240 | Glia |
| 1241 | Microglia |
| 1242 | Innate immune system |
| 1243 | Symptom networks |
| 1244 | Neural plasticity |
| 1245 | Patient experts |
| 1246 | Partnership |
| 1247 | Neuropathophysiology |
| 1248 | Digital phenotyping |
| 1249 | Scales |
| 1250 | Disease severity |
| 1251 | Personalized treatment |
| 1252 | Virtual reality |
| 1253 | Avatars |
| 1254 | Complement cascade |
| 1255 | Immunity |
| 1256 | Innate immunity |
| 1257 | Long acting injectable |
| 1258 | social |
| 1259 | UHR |
| 1260 | HiTOP |
| 1261 | SPINS |
| 1262 | biomarcadores |
| 1263 | neuroimagen |
| 1264 | engoque holístico |
| 1265 | Pain |
| 1266 | Opiates |
| 1267 | fMRI |
| 1268 | DTI |
| 1269 | Meta-analysis |
| 1270 | Motivational interviews |
| 1271 | App |
| 1272 | Registries |
| 1273 | Glutamine |
| 1274 | Αιτιολογία |
| 1275 | Γενετική |
| 1276 | Consensus |
| 1277 | Staging |
| 1278 | Exome sequencing |
| 1279 | TBAR |
| 1280 | Folate |
| 1281 | Gut microbiota |
| 1282 | Psychobiotic |
| 1283 | Prebiotic |
| 1286 | Health economics |
| 1287 | Migration |
| 1288 | Risk factors |
| 1289 | Psychoeducation |
| 1290 | Asesoramiento |
| 1291 | síntomas negativos |
| 1292 | Primeros episodios |
| 1293 | outils d'e-santé |
| 1294 | sélection de traitement de la schizophrénie |
| 1295 | Guidelines |
| 1296 | Pro-inflammatory mediators |
| 1297 | Interleukin |
| 1298 | TNF |
| 1299 | pre-clínico |
| 1300 | ADHD |
| 1301 | inattention |
| 1302 | hyperactivity |
| 1303 | impulsivity |
| 1304 | Absenteeism |
| 1305 | Presenteeism |
| 1306 | Employee |
| 1307 | Ultra high risk |
| 1309 | Neurocognitive training |
| 1310 | BNSS |
| 1311 | SNS |
| 1312 | SSRI |
| 1313 | PDGF |
| 1314 | Dopaminergic |
| 1315 | Glutamatergic |
| 1316 | IL-17 |
| 1317 | CRP |
| 1320 | Amygdala |
| 1321 | Prefrontal cortex modulation |
| 1322 | Behaviour |
| 1323 | Adherencia |
| 1324 | Asesoriamiento |
| 1325 | ILP |
| 1326 | Incidencia |
| 1327 | carga |
| 1328 | Side-effects |
| 1329 | Measure-cased care |
| 1330 | PANSS-6 |
| 1331 | Coordinated Specialty Care |
| 1332 | Life trajectory |
| 1333 | Φροντιστής |
| 1334 | Cognitive |
| 1335 | prise en charge |
| 1336 | résistance |
| 1338 | BDNF |
| 1339 | Gestão de doenças |
| 1340 | Gestão de pacientes |
| 1341 | Remissão |
| 1342 | Tratamento |
| 1343 | Cognição |
| 1344 | Curso de uma doença |
| 1345 | Saúde física |
| 1346 | Reincidência |
| 1347 | Resposta inadequada |
| 1348 | Etiologia Pesquisa Genética |
| 1349 | Pesquisa |
| 1350 | Primeiro episódio |
| 1351 | Imagiologia |
| 1353 | symptômes négatifs |
| 1355 | Functional movement disorders |
| 1357 | 징후 |
| 1358 | Essential tremor |
| 1359 | Aeitology |
| 1360 | Stakeholders |
| 1361 | Collaboration |
| 1362 | Innovation |
| 1363 | Sleep hygiene |
| 1364 | Aβ42 oligomer |
| 1365 | Amyloid-β |
| 1366 | Astrocyte |
| 1367 | Neurotoxin |
| 1374 | depot medication |
| 1375 | long acting injectables |
| 1376 | Diseasase management |
| 1377 | Patient-centricity |
| 1378 | Rational prescribing |
| 1379 | Nomenclature |
| 1380 | Anhedonia |
| 1381 | Intervention |
| 1382 | High risk groups |
| 1383 | Apathy |
| 1384 | Long acting injectables |
| 1385 | Treatments |
| 1386 | Sympotoms |
| 1387 | Pharamacology |
| 1388 | Emotional blunting |
| 1389 | Agression |
| 1390 | Oxytocin |
| 1391 | Vasopressin |
| 1392 | Caffeine |
| 1393 | Adverse early life experiences |
| 1394 | Depression; Inflammation |
| 1396 | Alphasynuclein |
| 1397 | Disease modifying treatment |
| 1398 | Prodomal PD |
| 1399 | Congress highlights |
| 1400 | Neuropsychiatric symptoms |
| 1401 | Algorithms |
| 1402 | Sex difference |
| 1403 | Telemedicine |
| 1404 | Movement disorders |
| 1405 | Tele-education |
| 1406 | Telerehabilitation |
| 1407 | Telemetry |
| 1408 | Tics and Tourette syndrome |
| 1409 | Chatbot |
| 1410 | AI |
| 1411 | Adverse effects |
| 1412 | Pharmacogenomics |
| 1413 | Polygenic risk score |
| 1414 | Genome-wide association studies |
| 1415 | Melatonin |
| 1416 | Circadian rhythm |
| 1417 | Blue-depleted light |
| 1418 | Duration of hospitalization |
| 1419 | Neuroradiologist |
| 1420 | Resilience building |
| 1421 | Media |
| 1422 | Biomarker |
| 1423 | Research Pharmacology |
| 1424 | Metabolic |
| 1425 | LAC |
| 1426 | Lactate |
| 1427 | Trait qualifiers |
| 1428 | Epidemiology Physical health |
| 1429 | Mortality |
| 1430 | Mortality Gap |
| 1431 | Harm reduction |
| 1432 | Functional |
| 1433 | SNRI |
| 1434 | Treatment. |
| 1435 | Hypomania |
| 1436 | apps |
| 1437 | Transdiagnostic |
| 1438 | Social withdrawal |
| 1442 | First episode psychosis. |
| 1443 | Cognitive bias |
| 1444 | Neural circuits |
| 1445 | Onset of effect |
| 1446 | Disease treatment |
| 1447 | focalización |
| 1448 | p value |
| 1449 | Effect size |
| 1450 | Number needed to treat (NNT) |
| 1451 | Number needed to harm (NNH) |
| 1452 | Benefit-risk assessment |
| 1453 | 치료의 내성 |
| 1454 | 불충분한 반응 |
| 1455 | September 7 - 10 |
| 1456 | 2019 Copenhagen |
| 1457 | Denmark |
| 1458 | Venue: Bella Center Copenhagen |
| 1459 | Address: Center Blvd. 5 |
| 1460 | 2300 København |
| 1464 | 불안 |
| 1465 | 일 |
| 1466 | CSF |
| 1467 | Alzheimer’s continuum |
| 1468 | Health disparities |
| 1469 | Life course |
| 1470 | Prevelance |
| 1471 | DCTClock |
| 1472 | Integrated Cognitive Assessment (ICA) |
| 1473 | Asymptomatic AD |
| 1474 | Plaque-induced genes (PIGS) |
| 1475 | APOE |
| 1476 | TREM2 |
| 1477 | Motivational interviewing |
| 1478 | Neurotransmitters |
| 1479 | Serotonin transporter gene promoter region |
| 1480 | Cormorbidity |
| 1481 | Borderline personality disorder |
| 1482 | Substance use disorder |
| 1483 | Differantial Diagnosis |
| 1494 | Translational research |
| 1495 | 초조 |
| 1496 | 조증 |
| 1497 | Lundbeck symposiumet 2019 |
| 1498 | Lundbeck symposiumet |
| 1499 | Διαταραχή Χρήσης Αλκοόλ |
| 1500 | Lundbecksymposiet 2019 |
| 1501 | Lundbecksymposiet |
| 1502 | Functional gastrointestinal disorders |
| 1503 | Functional dyspepsia |
| 1504 | Irritable bowel syndrome |
| 1505 | 정신병 에피소드 |
| 1506 | Придържане |
| 1507 | Оценка |
| 1508 | Лечение на пациента |
| 1509 | Когниция |
| 1510 | Рецидив |
| 1511 | Отговор |
| 1512 | Възстановяване |
| 1513 | Реални доказателства |
| 1514 | Механизъм на действие |
| 1515 | Лечение на болестта |
| 1516 | Първи епизод |
| 1517 | Лечение |
| 1518 | Невротоксичност |
| 1519 | Продължително лечение |
| 1520 | Коморбидност |
| 1521 | Скрининг |
| 1522 | Качество на живот |
| 1523 | Депресия |
| 1524 | Когнитивен дефицит |
| 1525 | Функциониране |
| 1526 | Работа |
| 1527 | Недолекуван |
| 1528 | Научни изследвания |
| 1529 | Upoštevanje zdravljenja |
| 1530 | Vodenje bolnikov |
| 1531 | Preference bolnikov pri doseganju izida |
| 1532 | Metodologija navajanja preferenc |
| 1533 | Vodenje shizofrenije po meri bolnikov |
| 1534 | Ocenjevanje |
| 1535 | Obvladovanje bolezni |
| 1536 | Simptomi |
| 1537 | Zdravljenje |
| 1538 | Nevralno mreženje |
| 1539 | Funkcioniranje |
| 1540 | Vpogled |
| 1541 | Depresija |
| 1542 | Kognitivni primanjkljaj |
| 1543 | Delo |
| 1544 | Nezadostno upravljanje |
| 1545 | Shizofrenija in funkcioniranje |
| 1546 | Neizpolnjene potrebe |
| 1547 | Antipsihotiki |
| 1548 | Antipsihotiki delnega |
| 1549 | D2 antagonista |
| 1550 | Farmakologija delnega agonizma |
| 1551 | D2 |
| 1552 | Vloga delnega agonizma za D2 pri shizofreniji |
| 1553 | Delni agonist D2 in funkcioniranje |
| 1554 | Rezultati kliničnih študij in funkcioniranje |
| 1555 | Kognicija |
| 1556 | Kakovost življenja |
| 1557 | Znanstvene izmenjave |
| 1558 | Komorbidnost |
| 1559 | Presejanje |
| 1560 | Relaps |
| 1561 | Prva epizoda |
| 1562 | Nevrotoksičnost |
| 1563 | Dolgotrajno zdravljenje |
| 1564 | Ocena |
| 1565 | Raziskave |
| 1568 | Enfermedad de Parkinson |
| 1569 | Sexual Dysfunction |
| 1570 | Antidepressant induced sexual dysfunction |
| 1571 | PLISSIT model |
| 1572 | Asistencia |
| 1573 | Neurobiologia |
| 1574 | Estudio SHARP |
| 1575 | Hospitalización |
| 1576 | experto |
| 1577 | circuitos neuronales |
| 1578 | Resistente al tratamiento |
| 1579 | Investigación translacional |
| 1580 | Baune |
| 1581 | Bridges |
| 1583 | Aetiología |
| 1584 | Envejecimiento |
| 1585 | KOL |
| 1586 | enfermedad cardiovascular |
| 1587 | neuroinflamación |
| 1588 | beta amiloide |
| 1589 | Comorbilidad |
| 1590 | Curso de vida |
| 1591 | Prevalencia |
| 1592 | Astrocitos |
| 1593 | revisión |
| 1594 | Patogénesis |
| 1595 | Neurotoxina |
| 1596 | cuerpos Lewi |
| 1597 | Alfa-sinucleina |
| 1598 | respuesta inadecuada |
| 1599 | síntomas motores |
| 1600 | síntomas no motores |
| 1601 | Tratamientos |
| 1602 | Modificación del tratamiento |
| 1603 | Titulares de congreso |
| 1604 | síntomas neuropsiquiátricos |
| 1605 | Tremor esencial |
| 1606 | biomar |
| 1607 | Cuerpos de Lewi |
| 1608 | trastornos afectivos |
| 1609 | TLP |
| 1610 | episodios mixtos |
| 1611 | ICHD-3 |
| 1612 | Aura |
| 1613 | Headache |
| 1614 | Neuropeptides |
| 1615 | Calcitonin gene-related peptide |
| 1616 | CGRP |
| 1617 | Disability |
| 1618 | Triggers |
| 1619 | Monthly migraine days (MMD) |
| 1620 | Pituitary adenylate cyclase-activating polypeptide |
| 1621 | PACAP Chronic migraine |
| 1622 | Evolution |
| 1623 | Natural selection |
| 1624 | Pregnancy |
| 1625 | Infant colic |
| 1626 | Postdrome |
| 1627 | PACAP |
| 1628 | Neuromodulation |
| 1629 | Monoclonal antibody |
| 1630 | Ictal migraine |
| 1631 | Trigeminovascular system |
| 1632 | Patient education |
| 1633 | Approach to treatment |
| 1634 | Improving outcomes |
| 1635 | New treatment |
| 1636 | CGRP antagonists |
| 1637 | Cronic migraine |
| 1638 | Episodic migraine |
| 1639 | Hard-to-treat migraine |
| 1640 | Resources |
| 1642 | Treatment compliance |
| 1643 | Treatment tolerance |
| 1644 | Disease features |
| 1645 | Disease classification |
| 1648 | trastorno límite de la personalidad |
| 1649 | travail |
| 1650 | 위약 효과 |
| 1653 | Hyposmia |
| 1654 | Prodome |
| 1655 | Στίγμα |
| 1656 | Ποιότητα Ζωής |
| 1657 | α-synuclein |
| 1658 | Disease modifying therapy |
| 1659 | COVID-19 |
| 1660 | Pandemic |
| 1661 | Quarantine |
| 1662 | Social isolation |
| 1663 | CBTpsychosis |
| 1664 | CBTp |
| 1665 | Acceptance and Commitment therapy (ACT) |
| 1666 | Individualized Metacognitive Training (MCT+) |
| 1667 | Brain training |
| 1668 | Physical exercise |
| 1669 | Active-play video games |
| 1670 | Auditory hallucinations |
| 1671 | Cardiorespiratory fitness |
| 1672 | Reduce Trial |
| 1673 | HAMLETT |
| 1674 | TAILOR |
| 1675 | RADAR |
| 1676 | Taper |
| 1677 | Discontinuation |
| 1678 | Dose reduction |
| 1680 | Procjena |
| 1681 | Istraživanje |
| 1682 | Kvaliteta života |
| 1683 | Znanstvena razmjena |
| 1684 | Komorbiditet |
| 1685 | Probir |
| 1686 | Liječenje |
| 1687 | Pridržavanje terapije |
| 1688 | Pristup bolesniku |
| 1689 | Remisija |
| 1690 | Odgovor |
| 1691 | Oporavak |
| 1692 | Dokazi iz stvarnog života |
| 1693 | Mehanizam djelovanja |
| 1694 | Pristup bolesti |
| 1695 | Neuralno umrežavanje |
| 1696 | Uvid |
| 1697 | Neurotoksičnost |
| 1698 | Kontinuirano liječenje |
| 1699 | Shizofrenija i funkcioniranje |
| 1700 | Nezadovoljene potrebe |
| 1701 | Antipsihotici |
| 1702 | D2 parcijalni antagonisti |
| 1703 | Farmakologija D2 parcijalnih agonista |
| 1704 | Uloga D2 parcijalnih agonista u shizofreniji |
| 1705 | D2 parcijalni agonisti i funkcioniranje |
| 1706 | Rezultati kliničkih studija i funkcioniranje |
| 1707 | Tijek bolesti |
| 1708 | Satelitski simpozij |
| 1709 | Support for patients |
| 1710 | MCCB |
| 1711 | CANTAB |
| 1712 | Patient data |
| 1713 | Non-invasive devices |
| 1714 | Data tools |
| 1715 | Clinical aids |
| 1716 | Alcohol use |
| 1717 | Support for patients |
| 1718 | Relapse prevention |
| 1720 | Pandemic. Public health |
| 1721 | Burnout |
| 1722 | Deborah Dunsire |
| 1724 | TDP-43 |
| 1725 | Mild cognitive impairment |
| 1726 | Telomere |
| 1727 | Social distancing |
| 1728 | Self isolation |
| 1730 | Pandemia |
| 1731 | Estrés |
| 1732 | Cuarentena |
| 1733 | Distancamiento social |
| 1734 | Reserch |
| 1735 | Smoking |
| 1736 | Cannabis |
| 1737 | Dual diagnosis |
| 1738 | Co-morbid conditions |
| 1739 | EMA/I |
| 1740 | ACT |
| 1741 | ACT-DL |
| 1742 | Hallucinations |
| 1743 | Pandémie |
| 1744 | Quarantaine |
| 1745 | Isolation Sociale |
| 1746 | Κίνδυνος |
| 1747 | Support pour patients |
| 1749 | うつ病 |
| 1750 | Télémédecine |
| 1751 | Aide pour les patients |
| 1752 | Prévention des rechutes |
| 1753 | risque |
| 1754 | Santé publique |
| 1755 | 발병기전 |
| 1756 | Teret |
| 1757 | Prevencija |
| 1758 | Pandemija |
| 1759 | Stres |
| 1760 | Karatena |
| 1761 | Socijalna izolacija |
| 1762 | Telemedicina |
| 1763 | Podrška pacijentima |
| 1764 | Prevencija relapsa |
| 1767 | Karantena |
| 1771 | Negovalec |
| 1772 | preprečevanje |
| 1773 | javno zdravje |
| 1774 | Odziv |
| 1775 | Ozdravitev |
| 1776 | Resnični dokazi |
| 1777 | Mehanizem delovanja |
| 1778 | Breme |
| 1779 | Družbena izolacija |
| 1780 | Podpora bolnikom |
| 1781 | Preprečevanje ponovitve bolezni |
| 1782 | Counseling |
| 1783 | Cormobidity |
| 1784 | Non-oral therapy |
| 1785 | Device-assisted therapy |
| 1786 | Advanced disease |
| 1787 | Palliative care |
| 1788 | COVID-1D |
| 1789 | Family support |
| 1790 | Prevent recurrence |
| 1795 | 위험 |
| 1798 | Suicide Risk |
| 1800 | Drug seeking behaviours |
| 1801 | Metabolism |
| 1802 | Counselling |
| 1804 | Mood swing |
| 1805 | Manic and depressive |
| 1808 | emotions; MDD; antidepressant; response |
| 1810 | Childhood trauma |
| 1811 | Wellbeing |
| 1812 | SHAPS |
| 1813 | EEfRT |
| 1814 | Adverse childhood experience |
| 1815 | Microbiota-gut-brain pathway |
| 1817 | Psychiatric practice |
| 1818 | Composite International Diagnostic Interview (CIDI) 3.0 |
| 1819 | Bipolarity Index (BI) |
| 1821 | Metabolism |
| 1822 | Mixed features specifier |
| 1823 | CANMAT |
| 1824 | ISBD |
| 1826 | Neuronal correlates |
| 1827 | Heterogeneity |
| 1828 | Monoaminergic antidepressant |
| 1829 | Prefrontal cortex |
| 1832 | Lived-experience peer support |
| 1833 | Mobile application |
| 1834 | Mental health for all |
| 1835 | Access |
| 1836 | Investment |
| 1837 | Apps |
| 1838 | Digital peer support |
| 1839 | Pain syndromes |
| 1840 | Skin biopsy |
| 1841 | PART |
| 1842 | LATE |
| 1843 | Patient participation |
| 1844 | Brain health |
| 1845 | Patient communication |
| 1846 | Treatment trial period |
| 1847 | Addressing concerns |
| 1848 | Chronorisk |
| 1849 | Human model |
| 1850 | Chronotreatment |
| 1851 | Non-invasive monitoring |
| 1852 | Medication overuse |
| 1853 | Medication overuse headache |
| 1854 | Calcitonin gene-related protein |
| 1855 | Cortical spreading depression |
| 1856 | CSD |
| 1857 | Post-traumatic headache |
| 1858 | PTH |
| 1859 | Endorphins |
| 1860 | Enkaphalin |
| 1861 | Adrenaline |
| 1862 | epilepsy |
| 1863 | NbN |
| 1864 | Kontrola bolesti |
| 1865 | Postupanje s pacijentima |
| 1866 | Težina bolesti |
| 1867 | Personalizirano liječenje |
| 1868 | Meta-analiza |
| 1869 | Funkcija |
| 1870 | Radno mjesto |
| 1871 | Zajedničko odlučivanje |
| 1872 | Postavljanje ciljeva |
| 1873 | Alati |
| 1874 | Analiza puta |
| 1875 | Placebo efekt |
| 1876 | Ciljevi pacijenata |
| 1877 | Očekivanja pacijenata |
| 1878 | Adherencija |
| 1879 | Elderly |
| 1880 | Patients management |
| 1881 | Restore working ability |
| 1882 | Premorbid healthy state |
| 1883 | Elderly. Cognitive symptoms |
| 1884 | Communication |
| 1886 | Immune system |
| 1887 | Tauopathies |
| 1888 | Synaptic function |
| 1889 | Lysosome |
| 1890 | 2 min watch |
| 1891 | Post-partum |
| 1892 | Episodic |
| 1893 | Chronicity |
| 1894 | Prophylaxis |
| 1895 | Maintenance |
| 1896 | Integrated treatment |
| 1897 | Person-centered care |
| 1898 | Psychosocial intervention |
| 1899 | Exercise |
| 1900 | Chronic disease |
| 1901 | Clinical trial design |
| 1902 | Long-acting antipsychotic |
| 1903 | Randomized trials |
| 1904 | Cognitive behavior therapy |
| 1905 | ADHD |
| 1906 | Multi-variant pattern analysis |
| 1907 | Transition |
| 1908 | History |
| 1909 | Facial expression recognition |
| 1910 | Affective cognition |
| 1911 | Emotion Recognition |
| 1912 | Microbiota–gut–brain axis |
| 1913 | Empowerment |
| 1914 | Self-care |
| 1915 | DBSA |
| 1916 | Quality of care |
| 1917 | Quality assurance |
| 1918 | Psychopathology |
| 1919 | Cancer |
| 1920 | Population study |
| 1921 | Family study |
| 1922 | Pain |
| 1923 | Micro RNA |
| 1924 | Procalcitonin |
| 1925 | CALCA |
| 1926 | Cluster headache |
| 1927 | Estrogen |
| 1928 | Gender |
| 1929 | Trigeminal neuralgia |
| 1931 | Dugodjelujući antipsihotici |
| 1932 | Njegovatelj |
| 1933 | Dijagnoza |
| 1934 | Negovalci |
| 1935 | Potek bolezni |
| 1936 | Diagnoza |
| 1937 | Upravljanje z bolniki |
| 1938 | Adherenca Upravljanje s pacienti |
| 1939 | Ponovitev bolezni |
| 1940 | Dolgodelujoči antipsihotiki za injiciranje (LAI) |
| 1941 | Upravljanje s pacienti |
| 1942 | Cilji pacientov |
| 1943 | Pričakovanja pacientov |
| 1944 | Skupno sprejemanje odločitev |
| 1945 | Delovanje |
| 1946 | Delovno mesto |
| 1947 | Okrevanje |
| 1948 | Skupno sprejemenje odločitev |
| 1949 | Postavljanje ciljev |
| 1950 | Orodja |
| 1951 | Resnost bolezni |
| 1952 | Personalizirano zdravljenje |
| 1953 | Analiza na projekcijah |
| 1954 | Placebo učinek |
| 1955 | Patient-centered therapy |
| 1956 | Goal Attainment Scale |
| 1957 | Neuroscience-based nomenclature |
| 1958 | Early-phase schizophrenia |
| 1960 | Gender differences |
| 1961 | Women's mental health |
| 1962 | Cardiovascular |
| 1963 | Immuno-metabolic |
| 1964 | Smartphone App |
| 1965 | Social dysfunction |
| 1966 | Smartphone Apps |
| 1967 | Treatment resistant depression |
| 1968 | Difficult-to-treat depression |
| 1972 | 이미징 |
| 1973 | 아밀로이드 |
| 1974 | 타우 |
| 1975 | Probiotic(s) |
| 1976 | Symptoms. Treatment |
| 1977 | Neuronal plasticity |
| 1978 | Trauma |
| 1979 | Oxidative stress |
| 1980 | Novel treatments |
| 1981 | Psychosocial interventions |
| 1983 | Svjetski dan mentalnog zdravlja |
| 1984 | Svjetski dan mentalnog zdravlja Lived-experience peer support |
| 1985 | Biomarkeri |
| 1986 | Samoubojstvo |
| 1987 | Svetovni dan duševnega zdravja |
| 1988 | Dostopnost |
| 1989 | Vlaganja |
| 1990 | Dobro počutje |
| 1991 | Duševno zdravje |
| 1992 | Podpora z medsebojnimi izkušnjami |
| 1993 | Telepsihiatrija |
| 1994 | Mobilna aplikacija |
| 1995 | Duševno zdravje za vse |
| 1996 | Biomarkerji |
| 1997 | Samomori |
| 1998 | Svetovni dan duševnga zdravja |
| 1999 | Obladovanje bolezni |
| 2000 | Sladkorna bolezen |
| 2001 | Kardiovaskularna bolezen |
| 2002 | Sodelovanje v oskrbi |
| 2003 | Engagement |
| 2004 | Fear |
| 2005 | Neuroscience |
| 2006 | Dijabetes |
| 2007 | Kardiovaskularne bolesti |
| 2008 | Suradnički pristup skrbi |
| 2009 | Pristup |
| 2010 | Investicija |
| 2011 | Blagostanje |
| 2012 | Mentalno zdravlje |
| 2013 | Dobrobit |
| 2014 | Stručna podrška iz životnog iskustva |
| 2015 | Telepsihijatrija |
| 2016 | Mentalno zdravlje za sve |
| 2017 | Συνοδή πάθηση |
| 2018 | Етиология |
| 2019 | Биомаркери |
| 2020 | Диагноза |
| 2021 | Социална дисфункция |
| 2022 | Приложения за смартфон |
| 2023 | Дигитално фенотипиране |
| 2024 | WMHD |
| 2025 | Expert Views |
| 2028 | 마이크로바이옴 |
| 2029 | 면역체계 |
| 2030 | 미세아교세포 |
| 2031 | 염증 |
| 2032 | Disease phenotype |
| 2033 | Atypical symptoms |
| 2034 | Immunometabolic depression |
| 2036 | CGRP antibodies |
| 2037 | Interictal burden |
| 2038 | Anxious depression |
| 2039 | Phobias |
| 2040 | Diagonsis |
| 2041 | Depression in men |
| 2042 | Depression in elderly |
| 2044 | Amoloide |
| 2045 | Amiloide |
| 2046 | Gestión de la Patología |
| 2047 | Gestión del paciente |
| 2048 | Recaída |
| 2049 | Riesgos |
| 2050 | Evolución de la enfermedad |
| 2051 | Pronóstico |
| 2052 | Tratamientos de liberación prolongada |
| 2053 | Intervenciones psicosociales |
| 2054 | Brintellix |
| 2055 | Síntomas Tratamiento |
| 2056 | Immuno-metabolic. |
| 2057 | Gestión paciente |
| 2058 | Inyectables de Liberación Prolongada |
| 2059 | Gestión Patología |
| 2060 | Disfunción Social |
| 2061 | pps |
| 2062 | Fase temprana de esquizofrenia |
| 2063 | Zgodnje odkrivanje |
| 2064 | Zgodnje zdravljenje Stigma |
| 2065 | Dolgo delujoči antipsihotiki |
| 2066 | Zgodnje zdravljenje |
| 2067 | Skrbniki |
| 2068 | Upravljanje pacientov |
| 2069 | Fizično zdravje |
| 2070 | Zdravljanje |
| 2071 | Farmakologije |
| 2072 | Profilaksa |
| 2073 | Ohranjanje |
| 2074 | Rezistenca na zdravljenje |
| 2075 | Nezadovoljiv odgovor |
| 2076 | Klinična raziskava |
| 2077 | Genetika |
| 2078 | Patologija |
| 2079 | Postupanje s pacientima |
| 2080 | Tjelesno zdravlje |
| 2081 | Farmakologija |
| 2082 | First epizode |
| 2083 | Rano otkrivanje |
| 2084 | Rana intervencija |
| 2085 | Dizajn kliničkog ispitivanja |
| 2086 | Adherenca |
| 2087 | Napoved bolezni |
| 2088 | Functional communication |
| 2089 | Cognitive decline |
| 2090 | Evaluación |
| 2091 | Cefalea en racimo |
| 2092 | Estrógeno |
| 2093 | Género |
| 2094 | Cormorbilidad |
| 2095 | cnssypsium2020 |
| 2096 | Forgetfulness |
| 2097 | Normal aging |
| 2098 | Teleneurology |
| 2099 | Migraña |
| 2100 | Chronic medical illness |
| 2101 | Lack of motivation |
| 2102 | Pseudodementia |
| 2103 | Chronic migraine |
| 2104 | Barrier to care |
| 2105 | Computed tomography |
| 2106 | Magnetic resonance imaging |
| 2107 | TIA |
| 2108 | Thunderclap headache |
| 2109 | Healthy eating plate |
| 2110 | Migraine preventive eligibility |
| 2111 | Evidence |
| 2112 | Clinical trial endpoint |
| 2113 | Co-primary endpoints |
| 2114 | Most bothersome symptom |
| 2115 | PACAP-38 |
| 2116 | Hypothalamus |
| 2117 | Cephalgia |
| 2118 | Trigeminocervical |
| 2119 | Diagosis |
| 2120 | Mediator |
| 2121 | T cells |
| 2122 | Macrophages |
| 2123 | Trigeminal nerve |
| 2124 | Neural pathways |
| 2125 | Central nervous system |
| 2126 | Breastfeeding |
| 2127 | Elderly |
| 2128 | CGRP monoclonal antibody |
| 2129 | Gepant |
| 2130 | Dyskinesia |
| 2131 | Falls |
| 2132 | DMT |
| 2133 | Telenursing |
| 2134 | LRRK2 |
| 2135 | Astrocytes |
| 2136 | Immune response |
| 2137 | Resistance training |
| 2138 | Integrated care model |
| 2139 | Interdisciplinary |
| 2140 | Rehabilitation |
| 2141 | REM sleep behavior disorder |
| 2142 | α-synucleinopathy |
| 2143 | GBA1 |
| 2144 | SNAC |
| 2145 | Neurodegeneration |
| 2146 | Antibody |
| 2147 | Smartphone |
| 2148 | Sensors |
| 2149 | Cognitivo |
| 2150 | Riesgo |
| 2151 | Conception |
| 2152 | Teratogenicity |
| 2153 | Postpartum |
| 2154 | ICDH-3 |
| 2155 | Menopause |
| 2156 | HRT |
| 2157 | Perimenopause |
| 2158 | Postmenopause |
| 2159 | Wear-off |
| 2160 | Raziskava |
| 2161 | Razlike med spoloma |
| 2162 | Mentalno zdravje žensk |
| 2163 | Obvladovanje bolezni Zdravljenje |
| 2164 | Strojno učenje |
| 2165 | Podatki velikega obsega |
| 2166 | Aplikacije za pametne telefone |
| 2167 | Etiologija |
| 2168 | Socialna disfunkcija |
| 2169 | Digitalno fenotipiziranje |
| 2171 | Metabolismo |
| 2172 | Inflamación |
| 2173 | Obesidad |
| 2174 | Fisiopatología |
| 2175 | Psychiatry Connect |
| 2176 | Meeting series |
| 2177 | webinar |
| 2178 | Australia |
| 2179 | Webinar series |
| 2180 | Zgodnja faza shizofrenije |
| 2181 | PRELAPSE Study |
| 2182 | Correll |
| 2184 | Long-acting injectable antipsychotics; Schizophrenia; Healthcare utilization; Healthcare cost |
| 2188 | Conference |
| 2189 | injection à action prolongée |
| 2190 | Congrès |
| 2191 | Oestrogen |
| 2202 | Vaccine |
| 2203 | D2 receptor partial agonists |
| 2204 | Patient life engagement |
| 2207 | Psychiatry Connect; 2021 Meeting Series |
| 2208 | D2 receptor partial agonists |
| 2209 | Patient life engagement |
| 2210 | Melancholia |
| 2211 | Brain volume |
| 2212 | Adjunctive therapy |
| 2213 | Metabolic side effects |
| 2214 | Early onset schizophrenia |
| 2216 | Psychiatry Connect 2021 Meeting Series |
| 2217 | Psychiatry Connect 2021 Meeting Series; recap; PRELAPSE; 2021 |
| 2218 | Recap |
| 2219 | PRELAPSE |
| 2220 | Maintenance treatment |
| 2221 | Serotonin |
| 2222 | GWAS |
| 2223 | Dopamine partial agonists |
| 2225 | Ultra-high-risk |
| 2226 | Early intervention services |
| 2227 | Long-acting injectable |
| 2228 | Clinical outcome |
| 2229 | Immunometabolic |
| 2231 | Neuroplasticity |
| 2232 | Family intervention |
| 2233 | Family therapy |
| 2234 | Nonadherence |
| 2235 | Global mental health |
| 2236 | Inclusiveness |
| 2237 | Human rights |
| 2238 | Equity |
| 2239 | Collectiveness |
| 2240 | Language |
| 2241 | Air pollution |
| 2242 | Beta-amyloid |
| 2244 | 수면 |
| 2245 | 운동 |
| 2246 | 낙상 |
| 2247 | 식단 |
| 2248 | Föreläsning från Insikt Psykiatri 2020 |
| 2249 | Episode |
| 2250 | Patient-reported outcome measures |
| 2251 | Training & education |
| 2252 | Genomics |
| 2254 | Shared decision making |
| 2255 | Migraine burden |
| 2256 | Migraine-related disability |
| 2258 | 위험 요인 |
| 2259 | 위험 요소 |
| 2261 | Epigenetic |
| 2262 | Methylation |
| 2263 | ZBTB16 |
| 2264 | Cerebral organoids |
| 2265 | Agonista parcial del receptor D2 |
| 2266 | Compromiso del paciente |
| 2267 | Terapia |
| 2268 | Fenotipo de la enfermedad |
| 2269 | Síntomas atípicos |
| 2270 | Depresión Inmunometabólica |
| 2271 | Heterogeneidad |
| 2272 | Resistencia al tratamiento |
| 2273 | Efectos secundarios metabólicos |
| 2274 | Metacognición |
| 2275 | Realidad virtual |
| 2276 | Síntomas positivos |
| 2277 | Anticuerpo monoclonal CGRP |
| 2278 | Embarazo |
| 2279 | Lactancia |
| 2280 | Posparto |
| 2281 | Menopausia |
| 2282 | Perimenopausia |
| 2283 | Postmenopausia |
| 2284 | Estrógenos |
| 2285 | Φυσική υγεία |
| 2286 | Λειτουργικό αποτέλεσμα |
| 2287 | Reliability |
| 2288 | Healthcare professional |
| 2289 | Future of psychiatry |
| 2290 | Audit |
| 2291 | Sex |
| 2292 | Race |
| 2293 | Disparity |
| 2294 | Chronic |
| 2295 | Affective |
| 2296 | Metabolic abnormalities |
| 2297 | Vascular dementia |
| 2298 | Plasma biomarkers |
| 2299 | P-tau |
| 2300 | Mitochondrial dysfunction |
| 2301 | P53 |
| 2302 | Non-adherence |
| 2303 | Suboptimal adherence |
| 2304 | Atypical antipsychotic |
| 2305 | Recurrence |
| 2306 | Cardiovasular disease |
| 2307 | Psychosocial function |
| 2308 | Remisión |
| 2309 | Embotamiento Emocional |
| 2310 | Anxiety Disorder |
| 2311 | Primary care |
| 2312 | Behavioral changes |
| 2313 | Emotional Changes |
| 2314 | Long-term function |
| 2315 | Clinical high risk |
| 2316 | 불안 우울증 |
| 2317 | #recap #PsychiatryConnectRecap |
| 2318 | Meeting |
| 2319 | Psychiatry Connect Recap |
| 2320 | 유전체학 |
| 2322 | Stages of grief |
| 2323 | Case Report |
| 2324 | 저항 운동 |
| 2325 | Dermatological |
| 2326 | Reward processing |
| 2327 | Individualized treatment |
| 2328 | Metabolic risk |
| 2329 | Lewy Body dementia |
| 2330 | Treatment-resistant depression |
| 2331 | Neurological soft signs |
| 2332 | Reward |
| 2333 | Turn-taking anomalies |
| 2334 | Speech |
| 2335 | Precision psychiatry |
| 2336 | Tumor necrosis factor alpha |
| 2337 | Microglial activation |
| 2338 | Translocator protein |
| 2339 | Prostaglandin E2 |
| 2340 | Persistent |
| 2342 | Population |
| 2343 | Covid19 |
| 2344 | BDNF |
| 2345 | Smartphones |
| 2346 | Research. Screening |
| 2347 | Lifestyle intervention |
| 2348 | Type 2 diabetes |
| 2349 | Community care |
| 2350 | COH-FIT |
| 2351 | Coronavirus |
| 2352 | Geriatric psychiatry |
| 2353 | Health Inequalities |
| 2354 | Family risk |
| 2355 | Headspace |
| 2357 | Diagnostic criteria |
| 2358 | Patient voices |
| 2359 | Emotional health. Quality of life |
| 2360 | Cognitive function |
| 2361 | Disease burden |
| 2362 | 정서적 둔마 |
| 2363 | 무쾌감증(anhedonia) |
| 2364 | 외상 |
| 2365 | Course of diseas |
| 2366 | e Diagnosis |
| 2367 | Preventive treatments |
| 2368 | CGRP switching |
| 2369 | Acute symptoms |
| 2370 | Patient-reported outcomes |
| 2371 | Study |
| 2372 | Acute attack |
| 2373 | Patient preferences |
| 2374 | Electroencephalography |
| 2375 | Disease impact |
| 2376 | Impact |
| 2377 | Insights |
| 2378 | Κατάθλιψη |
| 2379 | Ψυχική Υγεία |
| 2380 | FINGER |
| 2381 | Structural MRI |
| 2382 | Pharmacoeconomic |
| 2383 | Number needed to treat |
| 2384 | Romance |
| 2385 | Sexuality |
| 2386 | Loneliness |
| 2387 | Love |
| 2388 | E-health |
| 2389 | E-mentalhealth |
| 2390 | DIALOG+ |
| 2391 | Solution-based |
| 2392 | Long COVID |
| 2393 | Psychological trauma |
| 2394 | Treatment gaps |
| 2395 | Healthcare access |
| 2396 | MOH |
| 2397 | Medication-overuse headache |
| 2398 | CaMEO study |
| 2399 | Schizophrenia; LAI; |
| 2400 | COVID-19 vaccines |
| 2401 | Sex differences |
| 2402 | Hormonal differences |
| 2403 | CGRP receptor |
| 2404 | Physical healt |
| 2405 | Infection |
| 2406 | World Suicide Prevention Day |
| 2407 | Digital |
| 2408 | Future |
| 2409 | Disorders of gut-brain interaction |
| 2410 | Treatment gap |
| 2411 | ICHD3 |
| 2412 | SNOOP |
| 2413 | PIN |
| 2414 | Abuse |
| 2415 | Photophobia |
| 2416 | Hyperacusis |
| 2417 | Allodynia |
| 2418 | Barriers |
| 2419 | Preventive therapy |
| 2420 | Withdrawal |
| 2421 | Neurofibrillary tangles |
| 2422 | Phosphorylated tau |
| 2423 | Diagnostic process |
| 2424 | Multidisciplinary team |
| 2425 | MDT |
| 2426 | Socioeconomic status |
| 2427 | Anti-CGRP monoclonal antibody |
| 2428 | Treatment discontinuation |
| 2429 | Side effects |
| 2430 | Myelin |
| 2431 | White matter |
| 2432 | Neuron |
| 2433 | Interleukins |
| 2434 | NRXN1 |
| 2435 | Neurexin |
| 2436 | Chronic trajectory |
| 2437 | Basic science |
| 2438 | Progression |
| 2439 | Remodeling |
| 2440 | Defensa |
| 2441 | Cefalea |
| 2442 | Carga de la migraña |
| 2447 | Aislamiento social |
| 2448 | Curso de la patología |
| 2449 | Estrés Oxidativo |
| 2450 | Ψύχωση |
| 2451 | Επιδημιολογία |
| 2452 | 원격의료 |
| 2453 | 정신의학의 미래 |
| 2454 | 5HT3 |
| 2455 | psychiatrie |
| 2456 | maladie psychiatrique |
| 2457 | modèles animaux |
| 2458 | SOBP |
| 2461 | Equidad |
| 2462 | Calidad de la atención |
| 2463 | Futuro de la psiquiatria |
| 2464 | Demencia con cuerpos de Lewy |
| 2465 | Trauma infantil |
| 2466 | Experiencia adversa infantil |
| 2467 | Comportamiento |
| 2468 | Función a largo plazo |
| 2469 | Alto riesgo clínico |
| 2470 | Persistente |
| 2471 | Riesgo muy alto |
| 2472 | Rehabilitación cognitiva |
| 2473 | Volumen cerebral |
| 2474 | Grupo de alto riesgo |
| 2475 | Pródromo |
| 2477 | Demencia vascular |
| 2479 | Na nevroznanosti temelječa nomenklatura (NbN) |
| 2480 | Zdravljenje osredotočeno na bolnike |
| 2481 | Lestvica doseganja ciljev |
| 2482 | Predklinično |
| 2483 | Raziskovanje |
| 2484 | Sindrom oslabljene (atenuirane) psihoze (APS) |
| 2485 | Sinaptično redčenje |
| 2486 | Hipokampus |
| 2487 | Prodrom |
| 2488 | Nezadosten odziv |
| 2489 | Podtipi |
| 2490 | Heterogenost bolezni |
| 2491 | Terapevtsko spremljanje zdravil |
| 2492 | Življenjski cilji |
| 2493 | Stroški |
| 2494 | Nadzor bolezni |
| 2495 | Bolnikovi cilji |
| 2496 | Shizofrenija |
| 2497 | 대기오염 |
| 2532 | 공중보건 |
| 2533 | 대유행 |
| 2535 | 원격 의료 |
| 2536 | 전화상담 |
| 2537 | 만성 코로나 |
| 2538 | 심리적 외상 |
| 2541 | Sueño |
| 2542 | Tumor |
| 2543 | Necrosis |
| 2544 | Proteína |
| 2546 | Epigenética |
| 2547 | Medicina personalizada |
| 2548 | Trauma Psicológico |
| 2549 | Epidemología |
| 2550 | Psiquiatría geriátrica |
| 2551 | Amiloidea |
| 2552 | PET de amiloide |
| 2553 | Contaminación atmosférica |
| 2554 | Disease-modifying drug (DMD) |
| 2561 | Τεχνολογία |
| 2563 | Mobile app |
| 2564 | Body mass index (BMI) |
| 2566 | Disease awareness |
| 2567 | Messaging |
| 2568 | PCR test |
| 2569 | Trigeminal |
| 2570 | Lockdown |
| 2571 | Switching |
| 2572 | MIDAS HIT-6 |
| 2578 | Real-world studies |
| 2579 | Assessment tools |
| 2581 | Digital medicine |
| 2582 | Early assessment |
| 2584 | Memory |
| 2586 | Life engagement |
| 2587 | Gene therapy |
| 2588 | Migraine |
| 2589 | Early in life adversities |
| 2590 | Adverse childhood experiences |
| 2591 | 기능적 결과 |
| 2593 | Patient-reported outcomes |
| 2594 | webinaari |
| 2595 | ajokyky |
| 2596 | psykiatriset sairaudet |
| 2597 | Korkeila |
| 2598 | Huuskonen |
| 2599 | Detoxification |
| 2600 | Treatment risk assessment |
| 2601 | Patient partnership |
| 2602 | Preventing hospitalization |
| 2604 | 学会共催セミナー |
| 2605 | Migraine without aura |
| 2607 | COVID-19 pandemic |
| 2608 | オンデマンド動画 |
| 2609 | セミナー・シンポジウム |
| 2611 | Citocinas |
| 2612 | Disregulación de citocinas |
| 2613 | Citocinas proinflamatorias |
| 2614 | Poligénicos |
| 2615 | Puntuación de riesgo |
| 2616 | Enfermedad Bipolar |
| 2617 | Imagen mental |
| 2618 | Estructura cerebral |
| 2619 | Polaridad |
| 2620 | desarrollo de fármacos |
| 2621 | Anomalías metabólicas |
| 2622 | L-acetilcarnitina |
| 2623 | Melancolia |
| 2624 | TDM melancólico |
| 2625 | inmunoterapia |
| 2626 | Diseminación cerebral |
| 2627 | Childhood adversity |
| 2628 | Maladaptive family function |
| 2631 | Accuracy |
| 2632 | Multimodal |
| 2633 | Brain structure |
| 2634 | Functional connectivity |
| 2635 | Personalised medicine |
| 2655 | Economic cost |
| 2656 | E-mental health |
| 2657 | Migraine prevelance |
| 2658 | Omics |
| 2659 | Proteomics |
| 2660 | Suicide prevention |
| 2661 | technologie |
| 2662 | Memoria |
| 2663 | Terapia de genes |
| 2664 | Diagnose |
| 2666 | antipsychotiques |
| 2667 | symposium satéllite |
| 2668 | lieu de travail |
| 2669 | Disease-Management |
| 2670 | Erstepisode |
| 2671 | Adhesion |
| 2672 | journée mondiale de la santé mentale |
| 2673 | Beurteilung |
| 2674 | Behandlung |
| 2675 | Symptome |
| 2676 | Unzureichendes Ansprechen |
| 2677 | Patientenmanagement |
| 2678 | LQ |
| 2679 | Forschung |
| 2680 | Risiken |
| 2681 | Erkrankungsverlauf |
| 2682 | Ätiologie |
| 2683 | Komorbidität |
| 2684 | Therapieresistenz |
| 2685 | Kognition |
| 2686 | Belastung |
| 2687 | Prävention |
| 2688 | Stigmatisierung |
| 2689 | Psychosen |
| 2690 | prise en charge précoce |
| 2691 | Pharmakologie |
| 2692 | Gestion des maladies |
| 2693 | Gestion des patients |
| 2694 | Insufficient response |
| 2695 | Therapy Resistance |
| 2696 | Load |
| 2697 | Stigmatization |
| 2700 | wird bearbeitet |
| 2701 | während der Krankheit |
| 2702 | Krankheitsmanagement |
| 2703 | Funktion |
| 2704 | Erkenntnis |
| 2705 | Patientenversorgung |
| 2706 | Auswertung |
| 2707 | Daten aus der realen Welt |
| 2708 | Wirksamkeit |
| 2709 | Leistung am Arbeitsplatz |
| 2710 | funktional Erholung |
| 2711 | Antipsychotika |
| 2712 | Ziele des Patienten |
| 2713 | körperliche Gesundheit |
| 2714 | Herzkreislauferkrankung |
| 2715 | Risikofaktor |
| 2716 | Gewichtszunahme |
| 2717 | Nebeneffekt |
| 2718 | Stoffwechselkrankheit |
| 2719 | la prise en charge de la maladie |
| 2720 | prise en charge du patient |
| 2721 | symptômes |
| 2722 | traitement |
| 2723 | abus médicamenteux |
| 2725 | Muistisairaus |
| 2726 | Psykiatriaa |
| 2727 | Geriatria |
| 2728 | Alzheimerintauti |
| 2729 | Uni |
| 2730 | Työuupumus |
| 2731 | Masennus |
| 2732 | No-adherencia |
| 2733 | estudios reales |
| 2734 | herramientas de evaluación |
| 2735 | Repsuesta inadecuada |
| 2736 | Compromiso de vida |
| 2737 | Sleep disorders |
| 2738 | Cortisol |
| 2739 | Cognitive Enhancers |
| 2740 | BDNF-TrkB signaling |
| 2741 | Neural network |
| 2742 | Monoaminergic |
| 2743 | Glutaminergic |
| 2744 | GABAergic |
| 2745 | Neurotransmission |
| 2747 | Engram |
| 2748 | Fear memory |
| 2749 | Thalamus |
| 2750 | Phenotype inflammation |
| 2752 | Recommendations |
| 2753 | Japan |
| 2755 | ECNP 2021; Affektive Störungen; Schizophrenie |
| 2756 | ECNP 2021; troubles affectifs; schizophrénie |
| 2757 | päänsärky |
| 2758 | migreeni |
| 2759 | psykiatrisen hoidon historia |
| 2760 | lääkehoito |
| 2761 | skitsofrenia |
| 2762 | psykiatria |
| 2763 | psykoosi |
| 2764 | Hoitomyöntyvyys |
| 2765 | Hoitoon sitoutuminen |
| 2768 | FinnGen |
| 2769 | Relapsi |
| 2770 | Ofer Agid |
| 2771 | Mielenterveys |
| 2772 | Avatar |
| 2773 | Lapsuuden trauma |
| 2774 | Psykiatrinen häiriö |
| 2775 | Depressio |
| 2776 | Lääketieteellinen päätöksenteko |
| 2777 | Diagnostiikka |
| 2778 | Psykitria |
| 2779 | Aivot |
| 2780 | Kliininen arviointi |
| 2781 | Epidemija |
| 2782 | Bolniki |
| 2783 | Ελλιπής απάντηση |
| 2784 | Ulcerative colitis |
| 2785 | Sitgma |
| 2786 | Opening Minds |
| 2787 | Mental health services |
| 2788 | Psykoterapia |
| 2789 | Gray matter |
| 2790 | Temporal lobe |
| 2791 | Second-generation antipsychotic |
| 2792 | First-generation antipsychotic |
| 2794 | Meninges |
| 2795 | Blood-brain barrier |
| 2796 | Σχιζοφρένεια |
| 2797 | Psychosis Agitation |
| 2798 | Vaccine |
| 2799 | Transport vehicle |
| 2800 | Chimerical molecules |
| 2801 | OGA inhibitors |
| 2802 | Synuclein |
| 2803 | Glial activation |
| 2804 | Ethnicity |
| 2805 | Cognitively unimpaired |
| 2806 | Latin America |
| 2807 | Africa |
| 2808 | Europe |
| 2809 | au cours de la maladie |
| 2810 | Loss of pleasure |
| 2811 | Social Anhedonia |
| 2812 | Caregiver burden |
| 2813 | Hyperglycemia |
| 2814 | JAMA |
| 2815 | メンタルヘルス、抑うつ、不安障害 |
| 2816 | メンタルヘルス |
| 2817 | 抑うつ |
| 2818 | 不安障害 |
| 2819 | 自殺 |
| 2820 | BMJ |
| 2821 | 不安 |
| 2822 | 心的外傷後ストレス障害 |
| 2823 | Lancet |
| 2824 | 大うつ病性障害 |
| 2826 | salud publica |
| 2827 | Coste económico |
| 2828 | Symptom control |
| 2829 | WMHD |
| 2830 | Psicosis temprana |
| 2831 | Circuitos cerebrales |
| 2832 | Salud del cerebro |
| 2833 | Red neuronal |
| 2834 | Monoaminérgico |
| 2835 | Glutaminérgico |
| 2836 | Neurotransmisión |
| 2839 | 統合失調症 |
| 2840 | 双極性障害 |
| 2841 | モバイルヘルス |
| 2843 | COVID-19後遺症 |
| 2844 | 認知機能障害 |
| 2845 | 悲嘆 |
| 2846 | グリーフ |
| 2847 | ICU |
| 2848 | スティグマ |
| 2849 | リアルワールドデータ |
| 2850 | RWD |
| 2853 | Social Behavior |
| 2854 | Sozialverhalten |
| 2855 | Music |
| 2856 | Music Therapy |
| 2857 | 孤独感 |
| 2858 | メタ解析 |
| 2860 | Phopho-tau |
| 2861 | Precision |
| 2862 | Aβ42 |
| 2863 | Well-being |
| 2864 | ウェルビーイング |
| 2865 | 睡眠障害 |
| 2866 | 自傷 |
| 2867 | 弁証法的行動療法 |
| 2868 | DBT |
| 2869 | Probabilistic model |
| 2870 | Deterministic model |
| 2871 | Environmental exposures |
| 2872 | ApoE ε4 |
| 2873 | バイオマーカー |
| 2874 | 逆境 |
| 2875 | 若年期の逆境 |
| 2876 | トラウマ |
| 2877 | 若年期のトラウマ |
| 2878 | aivoterveys |
| 2879 | neurologiset oireet |
| 2881 | Neurobiologiaa |
| 2882 | Cortical thinning |
| 2883 | Index |
| 2884 | Vulnerability |
| 2885 | Aging brain |
| 2886 | Functional |
| 2887 | Sex differences |
| 2889 | Early phase |
| 2890 | Women |
| 2891 | Affective symptoms |
| 2892 | Mood disorder |
| 2893 | 全般不安症 |
| 2894 | GAD |
| 2895 | 制限性食物摂取症 |
| 2896 | RCT |
| 2897 | パニック障害 |
| 2898 | ネットワークメタ解析 |
| 2899 | jornada |
| 2900 | Sustancias |
| 2901 | Trastorno por consumo de sustancias |
| 2902 | Experiencia traumática |
| 2903 | 暴力的行動 |
| 2904 | 中核的信念 |
| 2905 | core belief |
| 2906 | Uskomus |
| 2907 | Tiede |
| 2908 | Tutkimustieto |
| 2909 | Oikeellisuus |
| 2910 | Long-term outcomes |
| 2911 | 慢性疼痛 |
| 2912 | アクセプタンス＆コミットメントセラピー |
| 2913 | 認知行動療法 |
| 2914 | 疾病管理 |
| 2915 | 患者管理 |
| 2916 | 予防 |
| 2917 | 治療 |
| 2918 | 公衆衛生 |
| 2919 | 遠隔医療 |
| 2920 | IL-18 |
| 2921 | Precursor |
| 2922 | Suspiciousness |
| 2923 | UKバイオバンク |
| 2924 | 脳画像 |
| 2925 | 嗅覚 |
| 2926 | 認知機能 |
| 2927 | Patient-based assessment |
| 2928 | Treatment efficacy |
| 2931 | 家族焦点化療法 |
| 2932 | 思春期 |
| 2933 | 身体活動量 |
| 2934 | NICU |
| 2935 | 小児 |
| 2936 | 精神疾患 |
| 2937 | 自閉者 |
| 2938 | 母親 |
| 2939 | 産後うつ |
| 2940 | 音声分析 |
| 2941 | 性的マイノリティ |
| 2942 | 医療従事者 |
| 2943 | 遠隔精神医療 |
| 2944 | 救急医療 |
| 2945 | 周産期 |
| 2946 | 非医療従事者 |
| 2947 | 気温 |
| 2948 | 小学生 |
| 2949 | 精神神経症状 |
| 2950 | SARS |
| 2951 | MERS |
| 2952 | パーキンソン病 |
| 2953 | 肥満 |
| 2954 | 若年期 |
| 2955 | ヨガ |
| 2956 | 気分調節 |
| 2957 | メンタルヘルスケア |
| 2958 | 青少年 |
| 2959 | 心理的苦痛 |
| 2960 | 妊婦 |
| 2961 | 産後女性 |
| 2962 | 精神障害 |
| 2963 | 多遺伝子リスクスコア |
| 2964 | PRS |
| 2965 | 心血管疾患 |
| 2966 | 統合失調症スペクトラム障害 |
| 2967 | 孤独 |
| 2968 | 救急医 |
| 2969 | ネットワークメタアナリシス |
| 2970 | 燃え尽き症候群 |
| 2971 | レジリエンス |
| 2972 | 高齢者 |
| 2973 | アルツハイマー病 |
| 2974 | repetitive negative thinking |
| 2975 | 乳幼児期 |
| 2976 | 睡眠 |
| 2977 | 境界性パーソナリティ障害 |
| 2978 | BDP |
| 2979 | 末梢動脈疾患 |
| 2980 | PAD |
| 2981 | PHQ-8 |
| 2982 | EQ-5D VAS |
| 2983 | QQL |
| 2984 | 不妊治療 |
| 2985 | 急性ストレス反応 |
| 2986 | 遠隔心理診療 |
| 2987 | 若年者 |
| 2988 | 夜間人工光 |
| 2989 | ALAN |
| 2990 | 気分障害 |
| 2991 | 全般性不安障害 |
| 2992 | 強迫性障害 |
| 2993 | 機能的磁気共鳴画像法 |
| 2994 | 経済的苦境 |
| 2995 | WSAS |
| 2996 | GAD-7 |
| 2997 | 精神的健康 |
| 2998 | 重度精神疾患 |
| 2999 | SMI |
| 3000 | 少数民族 |
| 3001 | 小児がん |
| 3002 | 大学生 |
| 3003 | 医師 |
| 3004 | 自殺念慮 |
| 3005 | 妊娠悪阻 |
| 3006 | 生活習慣 |
| 3007 | 経済的な悪影響 |
| 3008 | 不安病状 |
| 3009 | 周産期女性 |
| 3010 | 雇用 |
| 3011 | 行動障害 |
| 3012 | 心筋梗塞 |
| 3013 | 死亡リスク |
| 3014 | メディア |
| 3015 | 認知機能リハビリテーション |
| 3016 | DNAメチル化データ |
| 3017 | 抗うつ薬 |
| 3018 | 再発リスク |
| 3019 | 高所得国 |
| 3020 | 身体疾患 |
| 3021 | 早産時 |
| 3022 | 父親 |
| 3023 | 認知症 |
| 3024 | 高齢 |
| 3025 | ワクチン |
| 3026 | 自殺未遂 |
| 3027 | 救急科 |
| 3028 | 社会不安障害 |
| 3029 | インターネット認知行動療法 |
| 3030 | 費用対効果 |
| 3031 | メンタルヘルス不調 |
| 3032 | 心不全 |
| 3033 | 不眠症 |
| 3034 | 神経疾患 |
| 3035 | 精神科診療 |
| 3036 | 日本 |
| 3037 | 児童福祉制度 |
| 3038 | 後遺症 |
| 3039 | 精神的苦痛 |
| 3040 | 注意欠如・多動症 |
| 3041 | 小児期 |
| 3042 | 中高年 |
| 3043 | 電話介入 |
| 3044 | 在宅勤務 |
| 3045 | 身体的・精神的ウェルビーイング |
| 3046 | CES-D |
| 3047 | CD-RISC10 |
| 3048 | 精神科遠隔診療 |
| 3049 | 虐待 |
| 3050 | 女性 |
| 3051 | BPD |
| 3052 | Disease modification |
| 3054 | graue Substanz |
| 3055 | matière grise |
| 3056 | Poor memory |
| 3057 | Panic Disorder |
| 3058 | 急性呼吸窮迫症候群 |
| 3059 | ARDS |
| 3060 | 外傷後ストレス障害 |
| 3062 | メンタルヘルスサービス |
| 3063 | Ansiedad |
| 3064 | Cuadro clínico depresión y ansiedad |
| 3065 | Respuesta al tratamiento |
| 3066 | Vortioxetina |
| 3067 | Estudio Reconnect |
| 3068 | 物質使用 |
| 3070 | 非臨床 |
| 3071 | リスク |
| 3072 | ストレス |
| 3073 | 薬理 |
| 3074 | 回復 |
| 3075 | アンへドニア |
| 3077 | Long acting therapy |
| 3078 | Long acting antipsychotic |
| 3079 | ガイドライン |
| 3080 | 日本うつ病学会 |
| 3081 | 炎症 |
| 3082 | Long-term outcome |
| 3083 | 核磁気共鳴画像 |
| 3084 | 脳ワイド関連解析 |
| 3085 | BWAS |
| 3086 | brain-wide association studies |
| 3087 | ゲノムワイド関連分析 |
| 3088 | Ischemic heart disease |
| 3089 | Systemic syndrome |
| 3091 | Treatment strategies |
| 3092 | Behavioral interventions |
| 3093 | Brain structure and function |
| 3094 | Inequality |
| 3095 | Underserved patient populations |
| 3096 | Bias |
| 3097 | Race and ethnicity |
| 3098 | Emergency treatment |
| 3099 | Treatment trends |
| 3100 | Acute treatment |
| 3101 | Treatment guidelines |
| 3103 | sistema nervioso central |
| 3104 | 双極性障害I型 |
| 3105 | Mobile health |
| 3106 | Prevalence |
| 3107 | Physiotherapy |
| 3108 | Speech and language therapy |
| 3109 | Mindfulness-based interventions |
| 3110 | Occupational therapy |
| 3111 | Real-life functioning |
| 3112 | Neural networks |
| 3113 | Augmented intelligence |
| 3114 | Deep learning |
| 3116 | Digital navigator |
| 3117 | Asynchronous telehealth |
| 3118 | Telehealth |
| 3119 | Digital clinic |
| 3120 | Social determinants |
| 3121 | Functionality |
| 3122 | Social processing |
| 3123 | Emotion regulation |
| 3124 | Mentalizing |
| 3125 | Life satisfaction |
| 3126 | Multiple sclerosis |
| 3127 | Parkinson’s disease |
| 3128 | South America |
| 3129 | Patient-centric |
| 3130 | 遺伝子 |
| 3131 | ultra-rare coding variants |
| 3132 | Pisa syndrome |
| 3133 | Tailored therapy |
| 3134 | Patient views |
| 3136 | Endocannabinoids |
| 3137 | Exosomes |
| 3138 | mRNA translation |
| 3139 | Electronic wearable devices |
| 3140 | Salience network |
| 3141 | Joint decision-making |
| 3142 | Treatment outcomes |
| 3143 | BrainChart |
| 3144 | 脳の発達 |
| 3181 | Emotional processing |
| 3183 | Anti-inflammatory cytokines |
| 3184 | Pro-inflammatory cytokines |
| 3193 | Chronification |
| 3194 | Tailored treatment |
| 3195 | Migraine triggers |
| 3198 | 日本人 |
| 3199 | 突然変異 |
| 3200 | 脳 |
| 3201 | ニューロン |
| 3204 | Digital biomarkers |
| 3206 | Migraine disability |
| 3207 | Patient burden |
| 3208 | Treating the whole patient |
| 3209 | Measuring disease |
| 3211 | Disease mechanisms |
| 3212 | Future research |
| 3213 | a-synuclein |
| 3214 | REM sleep behaviour disorder |
| 3215 | Disease-modifying therapies |
| 3216 | Family life |
| 3217 | Work life |
| 3218 | Riscos |
| 3219 | Psicose |
| 3220 | Low mood |
| 3221 | Low interest |
| 3222 | Daily functioning |
| 3223 | Patient compliance |
| 3224 | Ansiedade |
| 3225 | Medo |
| 3226 | Neurociência |
| 3227 | 診断 |
| 3228 | 鑑別診断 |
| 3229 | 精神科受療 |
| 3230 | 救急患者 |
| 3231 | Cardiometabolic risk factors |
| 3232 | Hypertension |
| 3233 | Physical inactivity |
| 3235 | Frontotemporal dementia |
| 3236 | Neuropsychological testing |
| 3239 | Healthcare resource utilization |
| 3240 | Preventive treatment |
| 3241 | Economic burden |
| 3243 | Cognitive training |
| 3244 | Psychosocial rehabilitation |
| 3246 | N-methyl-D-aspartate (NMDA) receptor |
| 3247 | Positive and Negative Syndrome Scale (PANSS) |
| 3249 | SCHEMA |
| 3250 | Osteopontin |
| 3251 | Predominant negative symptoms |
| 3252 | TRANSD |
| 3253 | Personalized management |
| 3254 | Functional remission |
| 3255 | Digital platform |
| 3259 | 非器質性精神病 |
